CA1297788C - Treatment of aids virus with recombinant human alpha interferon - Google Patents

Treatment of aids virus with recombinant human alpha interferon

Info

Publication number
CA1297788C
CA1297788C CA000549813A CA549813A CA1297788C CA 1297788 C CA1297788 C CA 1297788C CA 000549813 A CA000549813 A CA 000549813A CA 549813 A CA549813 A CA 549813A CA 1297788 C CA1297788 C CA 1297788C
Authority
CA
Canada
Prior art keywords
recombinant human
interferon
htlv
iii
interferon alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000549813A
Other languages
English (en)
French (fr)
Inventor
Judith Feinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25446188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1297788(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of CA1297788C publication Critical patent/CA1297788C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA000549813A 1986-10-22 1987-10-21 Treatment of aids virus with recombinant human alpha interferon Expired - Lifetime CA1297788C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92192286A 1986-10-22 1986-10-22
US921,922 1986-10-22

Publications (1)

Publication Number Publication Date
CA1297788C true CA1297788C (en) 1992-03-24

Family

ID=25446188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000549813A Expired - Lifetime CA1297788C (en) 1986-10-22 1987-10-21 Treatment of aids virus with recombinant human alpha interferon

Country Status (8)

Country Link
EP (1) EP0266940B1 (enExample)
JP (1) JPS63104929A (enExample)
AT (1) ATE83381T1 (enExample)
CA (1) CA1297788C (enExample)
DE (1) DE3783122T2 (enExample)
ES (1) ES2052579T3 (enExample)
GR (1) GR3006999T3 (enExample)
OA (1) OA08768A (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT99837A (pt) * 1990-12-21 1992-12-31 Schering Corp Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas
MX9307733A (es) * 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
FR2713657B1 (fr) * 1993-12-13 1996-03-01 Transgene Sa Nouveaux vecteurs pour le traitement du sida.
PL2294066T3 (pl) 2008-04-28 2015-02-27 Janssen Pharmaceutica Nv Benzimidazole jako inhibitory hydroksylazy prolilowej
CA2853455C (en) 2011-10-25 2019-12-03 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法

Also Published As

Publication number Publication date
ATE83381T1 (de) 1993-01-15
GR3006999T3 (enExample) 1993-06-30
JPS63104929A (ja) 1988-05-10
EP0266940A1 (en) 1988-05-11
DE3783122T2 (de) 1993-04-22
OA08768A (fr) 1989-03-31
DE3783122D1 (de) 1993-01-28
ES2052579T3 (es) 1994-07-16
EP0266940B1 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
Lane et al. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma
Montefiori et al. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
Nair et al. Immunoregulatory effects of morphine on human lymphocytes
MANO et al. Fetal human immunodeficiency virus type 1 infection of different organs in the second trimester
Larder et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
Hall et al. Multiple isolates and characteristics of human T-cell leukemia virus type II
YAMAMOTO et al. Human alpha-and beta-interferon but not gamma-suppress the in vitro replication of LAV, HTLV-III, and ARV-2
Lee et al. Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus
Fauci Current issues in developing a strategy for dealing with the acquired immunodeficiency syndrome.
Vendrame et al. Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer
Wyatt et al. Persistent infection of rabbits with bovine leukemia virus associated with development of immune dysfunction
US7341731B2 (en) HIV-2 antigen compositions
TURANO et al. Inhibitory effect of papaverine on HIV replication in vitro
DEGRÉ et al. Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders
Frumkin et al. Acute infection of Macaca nemestrina by human immunodeficiency virus type 1
Berglund et al. Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-α and zidovudine
CA1297788C (en) Treatment of aids virus with recombinant human alpha interferon
Barré-Sinoussi et al. Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS
Sherman et al. Identification of human T cell leukemia/lymphoma virus type I antibodies, DNA, and protein in patients with polymyositis
NAGASHUNMUGAM et al. Human submandibular saliva specifically inhibits HIV type 1
Fan et al. Interferon‐γ protects primary monocytes against infection with human immunodeficiency virus type 1
Kiinzi et al. Identification of human immunodeficiency virus primary isolates resistant to interferon-α and correlation of prevalence to disease progression
Preble et al. Interferon-Induced 2′–5′ Oligoadenylate Synthetase During Interferon-α Therapy in Homosexual Men with Kaposi's Sarcoma: Marked Deficiency in Biochemical Response to Interferon in Patients with Acquired Immunodeficiency Syndrome
Cribier et al. Role of endogenous interferon in hepatitis C virus (HGV) infection and in coinfection by HIV and HCV
McMinn et al. Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community

Legal Events

Date Code Title Description
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121205